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Radiopharmaceuticals based on 90Y are widely used  in  the treat  ment of ma  lig  nant deseases.
In or der to meet the re quire ments for their fu ture ap pli ca tion, a 90Sr/90Y gen er a tor was de vel -
oped and 90Y eluted from this lo  cally pro  duced  gen  er  a  tor was used for the radiolabelling of
the  DOTA-con ju gated  somatostatin  an a log [DOTA0,Tyr3] octreotate and the prep  a  ra  tion of
[90Y-DOTA0,Tyr3] octreotate (90Y-DOTATATE) for pep tide receptore radionuclide ther apy.
90Sr/90Y  gen er a tor  was  based  on  the  elec tro chem i cal  sep a ra tion  of  90Y from 90Sr in a  two-cy  -
cle elec  trol  y  sis pro  ce  dure. Three elec  trode cells were used to per  form both elec  trol  y  ses. In
both cy  cles, work  ing elec  trodes were kept on con  stant po  ten  tial. The pH of the so  lu  tion was
ad  justed to 2.7 of the value be  fore the elec  trol  y  ses.
The radionuclidic pu rity of the 90Y so lu tion was ana lysed by ITLC and ex trac tion pa per chro -
ma tog ra phy.  The  la bel ling  of  pep tide  (100  mg DOTATATE) with 90YCl3 was per formed at 95
°C for  30 min  utes. Radiochemical pu  rity was de  ter  mined by HPLC and chro  mato  graphic
sep  a  ra  tion, us  ing a solid SepPak C-18 col  umn.
Re sults  ob tained  con firmed    the  ef fi ciency  of  our  elec tro chem i cal  sep a ra tion  tech nique  and
qual ity  con trol  meth ods  for  90Y. The achieved ef  fi  ciency of the 90Sr/90Y  gen er a tor  above  96%
of the the o  ret i  cal value rep re  sents  a good ba  sis for the fur ther de  vel  op  ment of this gen  er  a  tor.
The la  bel  ling of the DOTATATE with 90Y ex  hib  ited a high ef  fi  ciency, too: there was less than
1% of 90Y3+in the 90Y-DOTATATE.
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IN TRO DUC TION
Radionuclide ther apy has been known for a long
time.  The  po ten tials  of  in ter nal  tar get  ra dio ther apy
have also been ac  knowl  edged for more than sixty
years, but the use of some novel radionuclides and
radiopharmaceuticals in the treat  ment of solid can  cer
has  rap  idly in  creased over the past  years.
Radionuclides with short phys  i  cal half-lives,
in the range from a few hours to a few days, could be
use  ful in  radionuclide ther  apy. Re  cently, Yt  -
trium-90 (90Y) has at  tracted  a lot of  at  ten  tion as a 
prom is ing ther a peu tic ra dio iso tope [1].  90Y has well 
known fa  vour  able fea  tures: a half-life (64.1 hour),
con sis tent with the rate of an ti body ac cu mu la tion in
tu  mours and no ac  com  pa  ny  ing  gamma ray   ra  di  a  -
tion in  its  de cay. Beta rays have an  in ter me di ate  en -
ergy of 0.9367 MeV(bmax
-  = 2.28 MeV) and a sta  ble
daugh ter  (90Zr). The ma  jor ad  van  tage of the use of
90Y in solid tu mours is  the con sid  er able path length 
of its b–  par ti cles  (r95 = 5.9 mm) in tis  sues.
90Y could be gen er ated by b– de cay of 90Sr (T1/2 = 
= 28.8 years) with which it ex ists in a sec  u  lar ra  dio  ac  -
tive equi lib rium. A scheme of the  break through is pre -
sented as
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Be  cause of its long half-life, 90Sr could be used
for an in def i nite  time, but this is also a se ri ous  lim  i ta -
tion for the de vel  op ment of an ad  e quate 90Sr/ 90Y gen -
er  a  tor sys  tem, as the pro  duc  tion of long-lived wastes
re quires care ful han dling and stor age. This is the prob -
lem that the use of such gen  er  a  tors poses be  fore  nu  -
clear  med i cine  de part ments.  Since  90Sr is a highly
toxic radionuclide, it is es  sen  tial that 90Sr should be
han dled  in  a  well-es tab lished,  con trolled  lab o ra tory,
by trained per  son  nel.
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*  Cor re spond ing  au thor;  e-mail:  djokici@vinca.rsFor the sep a ra tion of  90Y from 90Sr, sev eral sep a -
ra tion tech niques have been re ported, such as: ad sorp -
tion, sol vent ex trac tion, pre cip i ta tion, elec tro chem i cal 
sep a ra tion, and ion ex change [2-11]. The sep a ra tion of 
90Y from 90Sr  by  ad sorp tion  chro ma tog ra phy  on  the
col  umn is not con  ve  nient be  cause of the deg  ra  da  tion
of the col umn ma trix. Other tech niques, like the  sep a -
ra  tion of car  rier-free Y-90 from Sr-90 by cat  ion ex  -
change [12] or ion ex  change [13] sol  vent ex  trac  tion,
chro mato graphic  sep a ra tion  by  the  Eichrom-treated
col umn  [14],  the  ex trac tion  pa per  chro ma tog ra phy
(EPC) tech  nique [15-17] or with liq  uid mem  branes
[18, 19], could be use  ful for ob  tain  ing 90Y, but they
gave more or less spe  cific ra  dio  ac  tiv  ity, lower
radionuclidic pu  rity, as well as a higher quan  tity of
long-lived wastes.
The  elec tro chem i cal  method  was  sug gested  for
the sep a ra tion of pure  86Y from 86Sr and the pro duc tion 
of 86Y, an at trac tive ra dio iso tope for pos i tron emis sion
to mog ra phy  (PET)  [20-23].  Suc cess ful  elec tro chem i -
cal  sep a ra tions  of  90Y from 90Sr were pre  sented by
Venkatesh et al, as well as by Chukravarty et al, [14,
24].
The  cost-ef fec tive  avail abil ity  of  the  90Y from a 
gen  er  a  tor sys  tem makes it very at  trac  tive. As im  por  -
tant is the fact  that 90Y can  eas  ily bond to  many che  -
late mol  e  cules, which is the ba  sis  of its use in
radionuclide ther  apy. So, 90Y-la belled  com pounds,
such as pep tides, an ti bod ies, microspheres, ci trate and
phos  phates, were de  vel  oped as a new class of
radiotherapeutic agents. Some of these agents were
de  vel  oped at the Vin~a  In sti tute  [25-29].
The treat ment with radiolabelled somatostatin an -
a  logues was in  tro  duced in the 1990s, as a prom  is  ing 
ther apy  for  pa tients  with  in op er a ble  or  met a static
gastroentero-pancreatric neuroendocrine tu  mours
(GEP-NET) [30]. A  ma  jor  ity of GEPNET ex  hibit 
abun  dant lev  els of the somatostatin re  cep  tor which can
be vi  su  al  ized in pa  tients by the use of the radiolabelled
somatostatin  an a logue,  111In-diethylenetriamine
pentaacetic acid (DTPA)-octreotide [31]. There is  a lot
of data in lit  er  a  ture for the la  belled pep  tide-based
radiopharmaceuticals based on var  i  ous  radionuclides:
such as, 99mTc, 111In, for im  ag  ing, or 90Y, 177Lu ther  apy
[32-42].
90Y, as a b–-emit ting radionuclide with high ac tiv -
i  ties, has proved to be a suit  able ra  dio  iso  tope for  la  bel  -
ling  mod i fied  somatostatin  an a logues,  [DOTA0,Tyr3]
octreotide (90Y-DOTATOC) and [DOTA0,Tyr3]
octreotate (90Y-DOTATATE). Thus, 90Y-DOTATOC
and 90Y-DOTATATE were the next gen  er  a  tion of
radiolabelled com  pounds of the  pep  tide re  cep  tor
radionuclide ther  apy (PRRT) ther  apy to be   de  vel  oped
[43-45].
  Con sid er able  in ter est  con cern ing  the  use  of 
ther a peu tic  radiopharmaceuticals  ex ists  in  Ser bia.  On
the other hand, 90Y is an ex  pen  sive ra  dio  iso  tope,  re  -
quir  ing im  port on a large scale be  cause of the de  cay
loss, mak ing it   in con ve nient for ev ery day med i cal ap -
pli ca tion  in  the  im pov er ished  healthcare  sys tem  of
Ser bia.  There fore,  a  90Sr/90Y  gen er a tor  sys tem,  based
on  the  elec tro chem i cal  sep a ra tion  tech nique  and  pro -
ce  dures for de  ter  min  ing the radiochemical and
radionuclide im  pu  rity, were de  vel  oped [46]. Its use in
the cen  tral  ized radiopharmacy at the  Vin~a  In sti tute
was  es tab lished.
EX PER I MEN TAL
Ma te ri als
Ra dio ac tive  sources  90Sr as stron  tium ni  trate,
90Sr(NO3) in equi  lib  rium with 90Y in 1 M HNO3, with
a spe cific ac tiv ity of 2.70 GBq/mg Sr, ra dio ac tive con -
cen  tra  tion of 9.240 GBq/cm3, as well as car  rier-free
90YCl3 in a 0.05 M HCl so  lu  tion, ra  dio  ac  tive con  cen  -
tra tion 89.590 GBq/cm3,  were ob tained from the In sti -
tute of Atomic En ergy, Ra dio iso tope Cen tre, Polatom,
Po land.
[DOTA-Tyr3] octreotate (DOTATATE) in
lyophilised form was pro  vided from the In  sti  tute of
Atomic En ergy, Ra dio iso tope Cen tre Polatom, Po land.
[DOTA-Tyr3] octreotate TFA-salt of a pu  rity
>95 % was pro  vided by  Pi Chem (Graz, Aus  tria). All
other re  agents and sol  vents were sup  plied from com  -
mer cial  sources.
The potentiostat unit, Potentiostat/Galvanostat/
ZRA, Se  ries G 750, was com posed of  li  censed soft ware
FC 350 (Gamry In  stru  ments Inc., Warminster, Penn.,
USA).
The  equip ment  for  the  elec tro chem i cal  sep a ra -
tion was com  pleted with an elec  trol  y  sis cell made by
the Fac ulty of  Tech nol ogy and Met al lurgy,  Uni ver sity
of Bel  grade. A three-elec  trode  sys  tem was  housed in
quartz cells fit  ted with an acrylic cap. Two elec  trodes,
an an  ode and a cath  ode, with a sur  face of 2 cm2, were
high-pu  rity plat  i  num plats elec  trodes made by the In  -
sti  tute for Min  ing and Met  al  lurgy, Bor, Ser  bia. As a
ref er ence  elec trode,  sat u rated  cal o mel  elec trode
(SCE), (Gamry In  stru  ments, Inc.), in a ref  er  ent cell,
con  nected by Lugin’s cap  il  lary with an  elec  tro  chem  i  -
cal cell, was used. High-pu rity ar gon gas was pro vided  
from a lo  cal sup  plier.
The  ra dio ac tiv ity  of  90Sr and 90Y was mea  sured
in an ion  is  ation cham  ber (Capintec CRC-15 Beta
Count  ing Cal  i  bra  tor, Ramsey, N. J., USA) which con  -
tains  a  cal i bra tion  fac tor.  For  cal i brat ing  the  90Y dose
sec ond ary    cal i bra tion  source  of  90Sr, a  (ra  dio  ac  tive
so lu tion am poule No BW/21/10/R3-0.1, with an  ac tiv -
ity of 368.3 ± 9.6 kBq/Lg, dated De  cem  ber 15th,
2010), was used. A low level of ac tiv ity was mea sured
in the NaI(Tl) scin  til  la  tion coun  ter (Wallace Comp.
Gamma Coun  ter, LKB, Fin  land) by mea  sur  ing the
Bremmstrahlung  ra di a tions  of  90Sr and 90Y.
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per  formed us  ing the High Pres  sure Liq  uid
Chromatograph, Hewlett Packard 1050 S/N (Palo Alto,
Cal., USA), with an UV and gamma flow de  tec  tor
(Raytest Aus  tria GmbH, Langenzersdorf, Aus  tria), with
a RP C18 col umn (250 mm ´ 4.6 mm). Chro mato graphic 
sep  a  ra  tion was done by SepPak C-18 col  umn (Wa  ters,
Milford, Mass., USA), ac  ti  vated by 95% C2H5OH.
Prep a ra tion  of  the 
90Sr-
90Y  gen er a tor
90Sr-90Y  elec tro chem i cal  gen er a tor  was  based
on the elec  trol  y  sis of a mix  ture of 90Sr and 90Y in ni  -
trate form. The elec  trol  y  sis was per  formed in a quartz
cell with a of vol  ume 100 cm3 charged with 0.2 ml of
90Sr (NO3) in 1 M HNO3 (~1.85 GBq), while the elec  -
tro lyte of the to tal vol ume of 50 ml amounted to  0.003
M HNO3. The pH value was ad justed prior to the elec -
trol y sis with 3% am mo nia to 2.7 ± 0.2. Be fore the elec -
trol  y  sis, ar  gon was bub  bled for 15 minutes, pass  ing
through a glass tube which was dipped into the elec  -
trol y sis  so lu tion  and  plat i num  elec trodes  were  ac ti -
vated in 3 M HNO3.
The three-elec trode sys tem was housed in quartz 
cells fit ted with an acrylic cap. The work ing and aux il -
iary elec  trode,  sealed in a glass holder, were fully im  -
mersed in  the so  lu  tion, fac  ing each other. They were
main  tained at a very low dis  tance and the ref  er  ence
elec  trode (SCE) was kept very close to the cath  ode,
with out  touch ing  it.
Elec tro chem i cal  sep a ra tion  of 
90Y
The elec  trol  y  sis was per  formed in a two-step
pro ce dure . Dur ing the first elec trol y sis,  90Y was sep a -
rated from 90Sr  by  se lec tive  elec tro de pos it ing  of  90Y
on the plat  i  num cath  ode. This was achieved by ap  ply  -
ing a fixed po  ten  tial on the cath  ode of –2.5 V with re  -
spect to SCE. High-pu rity ar gon gas was con tin u ously
passed through the so  lu  tion to vent gases like H2, and
the so lu tion  con tin u ously mixed by a mag netic stir rer.
The first elec  trol  y  sis lasted 90 minutes. At the end of
the  se lec tive  elec tro de pos it ing  of  90Y, the elec  trodes
with the acrylic cap were re moved from the quartz cell, 
with  out switch  ing off the power sup  ply. Then the
power sup  ply  was switched off, the cath  ode plate  re  -
moved from the acrylic cap and washed with 10 ml of
ac  e  tone. Af  ter that, the cath  ode was trans  ferred to the
sec  ond quartz cell.
Dur ing the sec ond elec trol y sis, the so cold “pu ri -
fi ca tion  step”,  90Y was re  moved from the plat  i  num
elec  trode. In this step, the cath  ode from the first elec  -
trol y sis  con tain ing  90Y was used as an an  ode, but a
new plat  i  num elec  trode was used as a cath  ode. The
electrods were fully im  mersed in  the so  lu  tion, in a
sim i lar new elec tro lytic cell filled with fresh 0.0003 M
NaNO3 and pH ad  justed to 2.7 ± 0.2. This step of the
elec  trol  y  sis took 45 minutes and was per  formed as a
galvanostatic elec  trol  y  sis, at a fixed po  ten  tial of –2.5
V on the cath ode with re spect to SCE. Ar gon was con -
tin  u  ously passed through the so  lu  tion. In this elec  trol  -
y sis,  90Y was trans  ferred from the first plat  i  num elec  -
trode to the fresh plat  i  num elec  trode (cath  ode) and
then    de pos ited  on  it.  Af ter  the  elec tro de pos it ing  of
90Y, the cath  ode was taken out with  out switch  ing off
the cur  rent and washed with 10 ml ac  e  tone and then 
dis  solved by dip  ping it in a small vol  ume of 0.5 M
HCl, so as to ob  tain 90YCl3 suit  able for la  bel  ling.
In the ini tial  ex per i ments, 90Sr in equi lib rium with
90Y with rel  a  tively low ac  tiv  ity (~1.85 GBq) was used.
Qual ity  con trol  of 
90Y
The radionuclidic pu  rity of the 90Y  so lu tion  was
ana lysed  by  pa per  and  ITLC  chro ma tog ra phy.  Chro -
ma  tog  ra  phy pa  per Whatman N° 1 (18 cm ´ 2 cm) and
ITLC SG strips (14 cm ´ 1 cm)  of  nor mal sa line (0.9% 
NaCl) were used.
In or der to de ter mine the radionuclidic pu rity of the
90Y so lu tion, the so called  “BARC tech nique” was  used
[36, 37]. This method is  a com bi na tion of sol vent ex trac -
tion  and  pa per  chro ma tog ra phy  (ex trac tion  pa per  chro -
ma tog ra phy  - EPC). Whatman N° 1 (18 cm ´ 2 cm) pa  -
per  chro ma tog ra phy  strips  im preg nated  with  2-ethyl
hexyl, and  2-ethyl hexyl phosphonic acid (KSM-17) at
the point of spot ting were  used. Upon de vel op ment with
nor mal  sa line,  90Sr moves to the sol  vent front, leav  ing
90Y com pletely chelated and re tained at the point of spot -
ting. The ac  tiv  ity at the sol  vent front was es  ti  mated by
cut  ting the chromatograms in 1 cm pieces  and by mea  -
sur ing the  ra dio ac tiv ity in a NaI(Tl) scin til la tion coun ter. 
Radionuclidic pu  rity was cal  cu  lated as a per  cent  age of
the  to tal  spot ted  ac tiv ity. 
Prep a ra tion    and  qual ity
con trol  of 
90Y-DOTATATE
Prep  a  ra  tion  of DOTATATE and its
la bel ling  with 
90Y
The so  lu  tion of the DOTATATE was pre  pared un  der
asep tic  con di tions,  by  dis solv ing  the  [DOTA-Tyr3]
octreotate in ascor  bic acid so  lu  tion pH = 4.5. 0.5 ml
aliquots, dis  pensed in glass vi  als and freeze-dried for  24
hours. Thus,  sam ples with 100 mg DOTATATE and 50 mg
ascor bic acid were ob tained as lyophilised pow der in a vac -
uum.
The re con sti tu tion of the freeze-dried DOTATATE
was done in the same man  ner  for both the DOTATATE
ob  tained from Polatom, Po  land, and the one pre  pared at
the Vin~a In  sti  tute by add  ing 0.5 ml aliquots of ster  ile
nor  mal sa  line into the vi  als with the DOTATATE  and
mix ing.
The DOTATATE de  vel  oped at the  Vin~a In  sti  -
tute was la  belled by  add  ing  37 MBq of 90YCl3 only
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was per  formed at 95 °C, for 30 minutes. The heat  ing
and shak  ing was done in a tem  per  a  ture-con  trolled
heat ing bath. Af ter 30 minutes, the vial was cooled for
1-2 minutes in cold wa  ter to  room tem  per  a  ture and
ace  tic acid (50 mg/ml, pH 4.5) as a sta  bi  lizer  added.
The fi  nal vol  ume was ad  justed up to 3 ml. 
DOTATATE (Polatom) was la  belled with
1.85-5.55 GBq of 90YCl3. The con  tent of the  vial was
quan  ti  ta  tively trans  ferred to a vial with 90YCl3. The la  -
bel  ling pro  ce  dure was the same as for the sam  ples pre  -
pared in our Lab  o  ra  tory. These sam  ples of
90Y-DOTATATE (18.5-37.0 MBq/1 mg DOTATATE)
were pre  pared for the treat  ment of  pa  tients.
The ste  ril  ity of the la  belled com  pound was ob  -
tained by work  ing un  der asep  tic con  di  tions and with
ster il ized equip ment with  ad di tional  fil tra tion by  0.22 
mm fil  ters (Millipore).
Qual ity  con trol  of 
90Y-DOTATATE
The radiochemical pu  rity (RCP) of the 90Y-la  -
belled DOTATATE was de  ter  mined by HPLC and
solid phase sep  a  ra  tion us  ing SepPak C-18 mini col  -
umns (car  tridges). 
HPLC
A sam  ple of the 90Y-DOTATATE was ob  tained
by  dis solv ing  90Y-DOTATATE (5 ml) in a mix  ture of
500 ml 0.4 M so  dium ac  e  tate (pH 4.5) and 1 mg/ml
diethylen triamino pentaacetic acid (DTPA). The
HPLC anal  y  ses of the 90Y-DOTATATE sam  ple was
per formed by use of two sol vents: 0.1% trifluoroacetic 
acid (TFA) in wa  ter (sol  vent A) and acetonitrile (sol  -
vent B), by the gra di ent elu tion tech nique: 0-5 minutes 
95% B; 5-10 minutes: from 95%-0% B; 10-15 minutes 
0% B; from 15-20 minutes: from 0% to 95% B; 20-25
minutes: 85% B. The flow rate was 0.7 ml/minutes.
UV was de tected at 254 nm and ra dio ac tiv ity by  ra dio -
met ric  de tec tion. 
Solid phase SepPak sep  a  ra  tion
A SepPak C-18 mini col  umn was ac  ti  vated with
5 ml of 95% eth  a  nol (C2H5OH) and then washed with
10-15 ml of nor  mal sa  line (0.9% NaCl). A sam  ple of
the 90Y-DOTATATE (10-20 ml) dis  solved in 500 ml of
nor  mal sa  line was loaded onto the col  umn and then
washed out with 5 ml of nor mal sa line (frac tion A with
90Y3+). This step was fol  lowed by the wash  ing out of
the col umn with 5 ml of 95% C2H5OH (frac tion B with 
90Y-DOTATATE). 
RCP was cal cu lated as the per cent age of frac tion
B ac  tiv  ity, ac  cord  ing to the equa  tion
B
B
B A
[%]=
+
(2)
RE SULTS  AND  DIS CUS SION
Elec tro chem i cal  sep a ra tion  of
90Y and its qual  ity con  trol 
90Sr/90Y gen  er  a  tor was based on the elec  tro  -
chem i cal sep a ra tion of  90Y, ac cord ing to the  method of 
Chacravatry et al. [24]. In this gen  er  a  tor, the dif  fer  -
ence  be tween  the  elec tro chem i cal  po ten tials  of  Y3+
and Sr2+  was  ex  plored so as to achieve a clean and
quick  sep a ra tion  of  90Y from the par  ent radionuclide,
90Sr. The elec trol y sis was car ried out in an elec trol y sis
quartz cell,” as apotentiostatical elec trol y sis with a po -
ten tial  of  - 2.500 V ± 0.055 with re  spect to SCE. Dur  -
ing the first elec  trol  y  sis, the cur  rent was in  creased
from 730 mA to 745 mA as the elec  trol y  sis neared  the
end. The elec tro  lytic po  ten tial at the plat i  num cath  ode
was sta  ble dur  ing the elec  trol  y  sis, but could not be
main tained  at  - 2.50 V over the du  ra  tion of  the elec  -
trol  y  sis. It fell  to - 2.39 V,  still within the al  lowed
limit of <(±0.2)% plus 5 mV, in a con  stant volt  age
mode for an used potentiostatic unit. The pH was ad  -
justed at 2.7 ± 0.2. 
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Fig ure  1.  Equip ment  for  elec tro chem i cal  sep a ra tion,
Lab o ra tory  for  Ra dio iso topes,  Vin~a In  sti  tute (a); with
elec tro chem i cal  cell  (b)The  sec ond  elec trol y sis  was  ac com plished  at  a
sta ble  po ten tial  at  the  plat i num  cath ode  - 2.50 V dur  -
ing the elec  trol  y  sis, at a con  stant cur  rent of 100 mA.
The warm  ing  of the so  lu  tion dur  ing the elec  trol  y  sis
was re  mark  able, so that the cool  ing of the elec  trol  y  sis
cell was nec  es  sary. A  sep  a  ra  tion of the  H2 gas was
also de  tected, there  fore the stir  ring dur  ing the pro  cess
seems to be un  nec  es  sary. These con  di  tions had to en  -
sure the de po si tion yield above 90%. There was a need 
to con  vert 90Y into a  form  ap  pli  ca  ble to   med  i  cine
ther apy.
90Y ex  ists in sec  u  lar equi  lib  rium with its par  ent
iso tope  stron tium-90  (90Sc) a prod  uct of fis  sion re  ac  -
tion. There were many im  pu  ri  ties which had to  be re  -
moved,  in clud ing  pure  90Y.  Ra dio ac tive  90Sr as
90Sr(NO3)2 in equi  lib  rium with 90Y in 1 M HNO3, ob  -
tained from Polatom, Po  land, was of high
radionuclidic pu  rity (>99.5%), as well as of high
radiochemical pu  rity, so we ex  pected 90Y ob  tained by
the  elec tro chem i cal  sep a ra tion  method  from  the
90Sr/90Y gen er a tor to be of high radiochemical pu rity.
90Sr break  through is  a  ma  jor prob  lem of  ten en  -
coun  tered with the 90Sr/90Y  gen er a tor.  Be cause  90Sr is
a bone seeker, the up per limit of 90Sr in the 90Y so lu tion 
for hu  man use is 74 kBq (2 mCi) [24]. In or  der to pro  -
vide data con cern ing 90Sr con tam i na tion, the de vel op -
ment of  meth  ods for the de  ter  mi  na  tion of chem  i  cal
and radionuclide im  pu  rity was nec  es  sary.
The qual  ity of the said sep  a  ra  tion was in  ves  ti  -
gated  by  mea sur ing  the  ra dio ac tiv ity  of  the 90Y-so lu -
tion over  the course of time, fol  low  ing the half-life of
90Y. The de crease was fol lowed for 31 days i. e, a ~11.6 
half-life of 90Y. The ab  sence of de  vi  a  tion in the lower
part of the curve in fig. 2 con  firmed the ab  sence of
90Sr. In the  fig  ure pre  sented, the y-axis was given as
the log  a  rithm of ob  tained val  ues.
The radionuclidic pu  rity of the 90Y  so lu tion  was
ana lysed by pa per and ITLC chro ma tog ra phy. Chro ma -
tog ra phy  pa per  Whatman  N° 1 (18 cm ´ 2 cm) and
ITLC SG strips (14 cm ´ 1 cm) and 0.9% sa line so lu tion 
were  used for the anal  y  ses. Dur  ing the chro  ma  tog  ra  -
phy,  90Sr moved with the sol vent front, while 90Y stayed 
at the or  i  gin. As the mix  ture of 90Sr and 90Y was at low
ac  tiv  ity, at the megabecquerel level, the ac  tiv  ity at the
sol  vent front was es  ti  mated by use of dose cal  i  bra  tor
(Capintec CRC 15R, USA) which con tains a cal i bra tion 
fac tor and then com pared with the to tal spot ted ac tiv ity.
In ad  di  tion, the ac  tiv  ity of the so  lu  tion was tested and
mea  sured for a month. Com  par  a  tive re  sults of the
radiochemical pu  rity of 90Y be  fore and af  ter elec  trol  y  -
sis, ob  tained by pa  per chro  ma  tog  ra  phy, were given in
fig. 3(a) and fig. 3(b). The so  lu  tion of stron tium and yt  -
trium was in a bal ance, and its lay out  shown in fig. 3(a) 
where two peaks were vis i ble. The ab sence of a peak at
10 cm  rep  re  sent  ing  stron  tium fig. 3(b) in  di  cates that
the sep  a  ra  tion of yt  trium from stron  tium by elec  tro  -
chem i cal  sep a ra tion  was  suc cess ful.
In or  der to de  ter  mine the radionuclidic pu  rity of
the 90Y  so lu tion,  a  com bi na tion  of  sol vent  ex trac tion
and  pa per  chro ma tog ra phy  (ex trac tion  pa per  chro ma -
tog ra phy  EPC  - “BARC tech  nique”) was also used in
our ex per i ments. This method was sug  gested as a sen -
si tive and ac cu rate an a lyt i cal tech nique for the es ti ma -
tion of the pu  rity of 90Y [13]. The EPC pat  tern of 90Y
ob tained  upon  de vel op ment  with  nor mal  sa line  was
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Fig ure  2.  Ra dio ac tive  de cay  pat tern  of 
90Y pre  pared by
the  elec tro chem i cal  sep a ra tion  method  (>11  half  lives)
Fig  ure 3. (a) Stron  tium/Yt  trium in equi  lib  rium,
and  (b)  Yt trium  af ter  elec trol y sespre  sented in fig. 4. 90Sr moved to the sol  vent
frontleaving  90Y com  pletely chelated and re  tained at
the point of spot  ting.  Radionuclidic pu  rity was cal  cu  -
lated as a per  cent  age of the to  tal spot  ted ac  tiv  ity, es  ti  -
mated by mea sur ing  ra dio ac tiv ity in a dose cal i bra tor.
These re  sults have shown that a very low level of 90Sr,
not more than 0.2%, was found for 5 re peated elec trol -
y sis  pro ce dures.
Prep a ra tion    and  qual ity
con trol  of 
90Y-DOTATATE
Fifty-nine labellings of the com  mer  cially avail  -
able DOTATATE with 90YCL3 (Polatom, Po  land) done
over  the last five years were ob  served. Radiochemical
pu  rity re  sults of the 90Y-DOTATATE (RCP) ob  tained 
by solid phase SepPak sep a ra tion have shown that in the  
fifty-three la  belled batches pre  pared and la  belled ac  -
cord  ing to pro  ce  dure, only 49.0% of the batches were
on RCP over 99.0%, 73.6% had RCP higher than 98%,
84.9% had RCP higher than 95.0%, while  15.1% of all
pre  pared batches had more than 10% of Y3+.
A  part of the RCP re sults, along  with the con tent
of chem i cal im pu ri ties of  90Y in mg/ml (Cu, Ni, As, Pb,
Fe, Zn), were pre sented in tab. 1. Be cause of the in suf -
fi  cient  qual  ity con  trol of the re  sults for all of the used
batches of 90Y, RCP re  sults for only 33 la  belled sam  -
ples were pre  sented. As can  be seen from tab. 1, the
con tent of  met als ana lysed by the ICP OES spec trom  -
e  try method on the  day  of  their  pro  duc  tion was
within the lim its de clared by the man u fac turer (Cu, Ni, 
As < mg/ml, Pb < 5.0 mg/ml, Fe, Zn (<10.0 mg/ml). As
we have used 90YCl3 four days af  ter the date of pro  -
duc tion and qual ity con trol, the con tent of the el  e ment
could in  crease. Qual  ity con  trol re  sults for
90Y-DOTATATE were in ac  cor  dance with the con  tent
of listed met als in yt trium chlo ride: the higher the con -
tent of met als, es pe cially Pb, Fe, and Zn, the higher the
per  cent  age of free Y3+ in DOTATATE sam  ples la  -
belled with 90YCl3. As more than 15% of the pre  pared
batches con  tained  over  10% of Y3+, it was ob  vi  ous
that the in  flu  ence  of the listed met  als was high.
For pa  tient ap  pli  ca  tion, we have used the batches
on RCP over 98%, with  out any pu  ri  fi  ca  tion. For these
sam  ples of the 90Y-DOTATATE, there was (0.79 ±
±.0.58)% of 90Y3+in the 90Y-DOTATATE (mean ± stan  -
dard de  vi  a  tion SD), de  ter  mined by solid phase SepPak
sep a ra tion.
In the same way, the qual  ity con  trol of the batches
of DOTATATE de  vel  oped in  our Lab  o  ra  tory and la  -
belled with 90Y by the  90Sr/90Y  gen er a tor  (Vin~a In  sti  -
tute), was done 15 min  utes af  ter the prep  a  ra  tion  and re  -
peated af  ter 24 hours. The re  sults of the HPLC anal  y  ses
were pre  sented in  fig. 5. Radiochromatograms have
shown that  the pre pared sam ples of the 90Y-DOTATATE
(Rf = 12.532 - 12.822) were of  high radiochemical pu  -
rity, higher than 99% 15 min  utes af  ter prep  a  ra  tion and
higher than 96%, 24 hours af  ter prep  a  ra  tion, again with  -
out a  sta  bi  liser, con  firm  ing the  sta  bil  ity of the la  belled
com pound.
CON CLU SIONS
First re  sults of the use of the 90Sr/90Y  gen er a tor
have con  firmed the fea  si  bil  ity of   a prac  ti  cal ap  pli  ca  -
tion  of  the elec tro chem i cal sep a ra tion pro ce dure. This
seems  a su  pe  rior and low-cost tech  nique for a per  ma  -
nent sup ply of 90Y suit able for ther a peu tic ap pli ca tion. 
90Sr in equi lib rium with 90Y with a rel a tively low 
ac  tiv  ity (~1.85 GBq) was used for these ex  per  i  ments.
The ef  fi  ciency of the 90Sr/90Y  gen er a tor  was  above
96% of the the o ret i cal value and rep  re sents a good ba -
sis for fur  ther de  vel  op  ment of the 90Sr/90Y  gen er a tor.
These re  sults were also a con  fir  ma  tion that we have
suc  cess  fully com  pleted the equip  ment  of the 90Sr/90Y
elec tro chem i cal  gen er a tor  and  es tab lished  a  vi a ble
elec tro chem i cal  sep a ra tion  tech nique.
A  pro  ce  dure for pre  par  ing the DOTATATE and
its  la bel ling  with  90Y was de  vel  oped, too. The first la  -
bel  ling re  sults of DOTATATE with home-made 90Y
have shown  high radiochemical pu  rity, pos  si  bly con  -
firm  ing the good qual  ity of 90Y ob  tained from the
90Sr/90Y  gen er a tor.
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Fig ure  4.  Ex trac tion  pa per  chro ma tog ra phy  re sults
(EPC) of 
90Y from the 
90Sr/
90Y elec tro chem i cal gen er a tor
Fig  ure 5. HPLC radiochromatograms for 
90Y-DOTATATE
(Vin~a In  sti  tute); (a) 15 min  utes and (b) 24 hours af  ter
radiolabellingOur fu  ture plans in  volve   the set  ting up of ad  e  -
quate fa  cil  i  ties for han  dling  higher ac  tiv  i  ties  and for
stan  dard  iz  ing   pro  ce  dures for the pro  duc  tion and qual  -
ity con  trol of 90Y. Our  next step will be the  es  tab  lish  -
ment of pro  to  cols for the use of 90Y in the  la  bel  ling of
the DOTATATE and  other lig ands, as well as the task of
pro  vid  ing  the  nu  clear med  i  cine  com  mu  nity of Ser  bia
with ef  fi  cient radiopharmaceuticals for radionuclide
ther  apy  in the treat  ment of can  cer dis  eases.
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ELEKTROHEMIJSKA  SEPARACIJA  ITRIJUMA-90  U
ELEKTROHEMIJSKOM 90Sr/90Y  GENERATORU I  WEGOVO
KORI[]EWE  ZA RADIOOBELE@AVAWE  DOTA-KOWUGOVANOG 
SOMATOSTATINSKOG  ANALOGA  [DOTA0, Tyr3]  OCTREOTATE
Radiofarmaceutici bazirani na 90Y se sve vi{e koriste u tretmanu malignih oboqewa.
Da bi se izi{lo u susret budu}im potrebama, razvijen je 90Sr/90Y  gen er a tor.  Dobiveni  90Y eluat je
kori{}en za radioobele`avawe analoga kowugovanog DOTA somatostatina [DOTA0, Tyr3]
octreotate i pripremawe [90Y-DOTA0, Tyr3]  octreotate (90Y-DOTATATE), peptidnim receptorima u
radionuklidnoj terapiji. 90Sr/90Y gen  er  a  tor je baziran na elektrohemijskom odvajawu 90Y od 90Sr u
dvostepenoj elektrolizi. Sistem sa tri elektrode je kori{}en za obe elektrolize. U svakoj
elektrolizi potencijal radne elektrode je odr`avan konstantnim, dok je pH vrednost rastvora
bila pode{ena na 2,7. 
Radionuklidna ~isto}a rastvora 90Y je analizirana pomo}u in stant tankoslojne i papirne
hromatografije. Peptid (100 mg DOTATATE) je obele`avan 30 minuta na 95 °C. Radiohemijska
~isto}a je odre|ena pomo}u HPLC i hromatografskim razdvajawem koriste}i ~vrstu SepPak C-18
kolonu. 
Dobiveni rezultati potvr|uju efikasnost kako elektrohemijskog odvajawa, tako i
metodu za kontrolu kvaliteta 90Y. Postignuta efikasnost 90Sr/90Y generatora od 96% teorijske
vrednosti je dobra osnova za budu}i razvoj ovog generatora. Obele`avawe DOTATATE sa 90Y je
tako|e bilo visoko efikasno jer je bilo mawe od 1% slobodnog Y3+ u rastvoru nakon obele`avawa
90Y-DOTATATE.
Kqu~ne re~i: radionuklidna terapija, 90Y, 90Sr/90Y  gen  er  a  tor, radioobele`avawe,  
..........................90Y-DOTATATE